噬菌体与抗体类非传统窄谱抗菌药物临床研发进展与挑战

打开文本图片集

中图分类号：R978 文献标志码：A

AbstractDuring the research and development （R&D） of antibiotics， broad spectrum antibiotics have dominated foralong time，but their abuse may exertcollateral damage on the non-pathogenic bacteria and result in selective pressure， exacerbating the emergence of antimicrobial resistance （AMR）. In recent years，there have been some revival of narrow spectrum antibiotics，especially non-traditional products such as phage therapy and antimicrobial antibody，becauseof their significant clinicalvalue in precision therapyand delaying the burgeonof AMR.However， the lack of experience in the development of non-traditional products inevitably leads to numerous challenges，including how tostudy the pharmacokinetic/pharmacodynamic （PK/PD）characteristics of phages，how to selectantibody drug targetsandanimal models，and how tooptimize thedesignof clinical trials for narrow-spectrum antimibiotics.Despite these obstacles，the development of new narow-spectrum antimicrobials can help delay the developmentofAMR，avoid thedestructionofbeneficialflora，and providenew effectivetreatments forseriousmortal infection，which，along with theapplication ofrapid diagnostic techniques and strict antimicrobial stewardship，is expected to mitigate the global health threat posed by AMR.

Key wordsNarrow spectrum antibiotics; Phage therapy; Antimicrobial antibody; Clinical development

当前，抗菌药物耐药性（antimicrobial resistance，AMR）问题日益严峻，为全球卫生和社会经济带来了重大挑战，而新型抗菌药物研发管线的不足更加剧了细菌等微生物耐药危机。（剩余21985字）